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Abstract
Background: It is unclear whether influenza infection and associated co-infection are associated with patient-
important outcomes in critically ill immunocompromised patients with acute respiratory failure.
Methods: Preplanned secondary analysis of EFRAIM, a prospective cohort study of 68 hospitals in 16 countries. We
included 1611 patients aged 18 years or older with non-AIDS-related immunocompromise, who were admitted to
the ICU with acute hypoxemic respiratory failure. The main exposure of interest was influenza infection status. The
primary outcome of interest was all-cause hospital mortality, and secondary outcomes ICU length of stay (LOS) and
90-day mortality.
Results: Influenza infection status was categorized into four groups: patients with influenza alone (n = 95, 5.8%),
patients with influenza plus pulmonary co-infection (n = 58, 3.6%), patients with non-influenza pulmonary infection
(n = 820, 50.9%), and patients without pulmonary infection (n = 638, 39.6%). Influenza infection status was associated
with a requirement for intubation and with LOS in ICU (P < 0.001). Patients with influenza plus co-infection had the
highest rates of intubation and longest ICU LOS. On crude analysis, influenza infection status was associated with
ICU mortality (P < 0.001) but not hospital mortality (P = 0.09). Patients with influenza plus co-infection and patients
with non-influenza infection alone had similar ICU mortality (41% and 37% respectively) that was higher than
patients with influenza alone or those without infection (33% and 26% respectively). A propensity score-matched
analysis did not show a difference in hospital mortality attributable to influenza infection (OR = 1.01, 95%CI 0.90–1.
13, P = 0.85). Age, severity scores, ARDS, and performance status were all associated with ICU, hospital, and 90-day
mortality.
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Conclusions: Category of infectious etiology of respiratory failure (influenza, non-influenza, influenza plus co-
infection, and non-infectious) was associated with ICU but not hospital mortality. In a propensity score-matched
analysis, influenza infection was not associated with the primary outcome of hospital mortality. Overall, influenza
infection alone may not be an independent risk factor for hospital mortality in immunosuppressed patients.
Keywords: Influenza, Respiratory failure, Sepsis, Critical illness, Immunosuppression,
Introduction
Immunosuppressed patients admitted to an intensive
care unit (ICU) with acute respiratory failure have a very
high risk of mortality [1]. Acute respiratory failure can
have various etiologies, but pulmonary infection and its
sequelae remain the most frequent precipitants in those
that require ICU admission [2, 3]. Among the different
infectious agents which cause pulmonary infection in
immunocompromised patients, pneumonia caused by
influenza viruses has been associated with a particularly
high mortality rate [4].
Influenza infection can affect patients during pan-
demic periods (such as the H1N1 pandemic of 2008/
2009) or during seasonal epidemics. Factors associated
with the risk of a severe influenza infection during and
after pandemic periods have differed [5]. After the first
pandemic period in 2008 and 2009, influenza affected
particular subgroups, particularly obese and pregnant
patients [6, 7]. During the post-pandemic period, im-
munosuppression was a risk factor for both influenza in-
fection and ICU mortality [8]. Other factors associated
with greater severity of influenza infection are age, med-
ical comorbidities, and possibly co-infection. Bacterial
pulmonary co-infection has long been described in pa-
tients with influenza pneumonia, most commonly with
Staphylococcus aureus, Streptococcus pneumoniae, and
Haemophilus influenzae. Recognition of influenza infec-
tion is important because it allows the implementation
of appropriate infection control measures and specific
antiviral therapy. Furthermore, it might reduce inappro-
priate antibacterial administration.
Although bacterial co-infection has been associated
with increased mortality during the 2008/2009 pandemic
period [9], the impact of the combination of influenza
infection and bacterial or fungal co-infection on the out-
come of critically ill patients has been a matter of debate
[10]. Although influenza seems to be associated with
higher mortality rates in immunocompromised patients
[11, 12], the fraction of mortality attributable to either
influenza infection alone or influenza plus co-infection
has not been well defined. Our aim in the current study
was to examine the prevalence of influenza infection and
co-infection in critically ill immunocompromised pa-
tients admitted to the ICU with respiratory failure and
to determine whether influenza and associated
co-infection were associated with patient-important out-
comes in this group.
Methods
Study design and setting
The current study was a preplanned secondary analysis
of the EFRAIM study, a multinational prospective cohort
study in 68 centers in 16 countries. EFRAIM was per-
formed by the Nine-I (Caring for Critically Ill Immuno-
compromised Patients) study group [13]. The Nine-I
group includes critical care physicians from 16 countries
who have extensive experience in the management of
various groups of critically ill immunocompromised pa-
tients. Physician participation was voluntary, without fi-
nancial incentive. Participating investigators obtained
local institutional review board approval in accordance
with local ethics regulations.
Inclusion and exclusion criteria
Eligibility criteria were age ≥ 18 years, acute hypoxemic
respiratory failure (PaO2 < 60mmHg or SpO2 < 90% on
room air, or tachypnea > 30/min, or labored breathing or
respiratory distress or dyspnea at rest or cyanosis), need
for more than 6 L/min oxygen, respiratory symptom
duration less than 72 h, and non-AIDS-related immune
deficiency defined as hematologic malignancy or solid
tumor (active or in remission for less than 5 years), solid
organ transplant, long-term (> 30 days, any dose) or
high-dose (> 1 mg/kg/day) steroids, or any immunosup-
pressive drug taken in a high dosage or for more than
30 days. Exclusion criteria were postoperative acute re-
spiratory failure, admission after a cardiac arrest, ICU
admission exclusively to secure bronchoscopy, or refusal
of the patient or family to participate in the study.
Enrolment, data collection, and patient treatment
Participating ICUs enrolled patients from Nov. 5, 2015 to
Jul. 1, 2016. Prospective data were collected on patient
and disease characteristics, initial oxygenation strategy,
acute respiratory failure (ARF) etiology, associated organ
dysfunction, and patient outcomes at hospital discharge
and at day 90. The case report forms were sent to the co-
ordinating center in Paris for data entry by trained techni-
cians. The study was funded by the Groupe de Recherche
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en Réanimation Onco-Hématologique (GRRR-OH), an
academic non-profit French organization.
All management decisions were performed according
to standard local practice in each ICU. Diagnostic strat-
egies to identify the etiology of respiratory failure were
based on previous studies by the GRRR-OH
(11,18-20,23). ARF etiologies were based on pre-defined
criteria in each participating ICU (11,18-20,23). All diag-
noses were reviewed by two study investigators (from in-
dependent institutions) for coherence and for alignment
with accepted definitions. Oxygenation modalities, the
use of non-invasive ventilation, high-flow nasal oxygen,
or intubation was documented daily. Management of as-
sociated organ dysfunction, handling of immunosuppres-
sive drugs, or chemotherapy was decided by a physician
according to local and recommended practices. Intub-
ation decisions were left at the discretion of the care
team and based on the therapeutic response, clinical sta-
tus (including SpO2, respiratory rate, signs of respiratory
distress, and bronchial secretion volume), and patient’s
adherence to other oxygenation modalities.
Exposures, outcomes, and important covariates
The exposure of interest in this prespecified secondary
analysis of the EFRAIM study was influenza infection sta-
tus. Patients were divided into four groups for the pur-
poses of analysis: (1) influenza respiratory tract infection
alone, (2) influenza respiratory tract infection plus
co-infection, (3) non-influenza respiratory tract infection,
and (4) no suspected or confirmed respiratory tract infec-
tion. Influenza was diagnosed by the presence of positive
reverse transcription polymerase chain reaction (RT-PCR)
in immunosuppressed patients admitted to intensive care
units (ICUs) by a nasopharyngeal swab as it is the optimal
upper respiratory tract specimen collection method for in-
fluenza recommended by the CDC [14]. RT-PCR was not
performed in all patients but mainly in those in whom in-
fluenza infection was suspected.
Pulmonary co-infection was defined as either clinically
or microbiologically confirmed bacterial or invasive fun-
gal respiratory infection in patients with influenza
RT-PCR-positive respiratory tract infections [15].
The primary study outcome was all-cause hospital
mortality. Secondary outcomes included ICU length of
stay and 90-day mortality.
Data on important covariates were collected prospect-
ively. SOFA score was recorded at ICU admission [16].
Shock was defined as a need for vasopressors; acute kid-
ney injury (AKI) was defined as a need for renal replace-
ment therapy as decided by the treating physicians.
Statistical analysis
Continuous variables are reported as medians (inter-
quartile ranges [IQRs]) and categorical variables as
proportions. Data management allowed checking for
data inconsistencies that were solved by consensus.
Comparisons of proportions between the groups were
made using the χ2 test. Comparisons of continuous vari-
ables between the groups were made using the Wilcoxon
rank-sum test.
A propensity score (PS)-based approach was used to
limit the effect of bias on the between-group compari-
sons of hospital mortality. The propensity score was de-
fined as the probability that a patient with specific
baseline characteristics had influenza infection. We de-
veloped the PS using a logistic regression model that in-
cluded all baseline characteristics associated with illness
severity [2]: mechanical ventilation, age, Eastern Co-
operative Oncology Group (ECOG) performance status,
SOFA score at ICU admission, admission within first
hours of hospital admission, tobacco use, and underlying
disease (hematological or solid tumor or immune dis-
ease). To handle the missing values in these con-
founders, multiple imputations with chained equation
were used, where PS for each patient was averaged
across 30 completed datasets while PS matching used
these averaged scores. We matched individuals based on
their PS using a 1:1 matching algorithm without replace-
ment within a caliper of 0.15 standard deviation of the
logit of the PS. Final analyses on the matched dataset
were then performed using a logistic regression with a
random effects model on the paired observations, except
for the length of stay which we analyzed with a Cox ran-
dom effects model. Results are presented as odds ratio
(OR) with their 95%CI. Primary analyses were performed
on the complete cases, assuming missing completely at
random covariates. Sensitivity analyses for such assump-
tions were performed, based on multiple imputation
with chained equation. Details of the sample size calcu-
lation for the original EFRAIM study can be found else-
where [13]. A post hoc power analysis was not
considered appropriate for the current secondary ana-
lysis. All tests were two sided at the 0.05 significance
level. Analyses were performed using R statistical pack-
age (online at http://www.R-project.org).
Results
Baseline characteristics
Out of 1611 patients (60% men, median age 63 (IQR
54–71)) enrolled in the 68 participating ICUs, 4 expos-
ure groups were defined: patients with influenza respira-
tory tract infection alone (n = 95, 5.8%), patients with
influenza plus co-infection (n = 58, 3.6%), patients with
non-influenza respiratory tract infection (n = 820,
50.9%), and patient without suspected or confirmed re-
spiratory tract infection (n = 638, 39.6%). We also per-
formed additional analysis on 448 patients negative for
influenza and testing not done.
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Characteristics of each group are summarized in
Table 1. There were no statistically significant differences
between the groups regarding general clinical character-
istics including age and comorbidities. However, patients
with influenza tended to have a higher body mass index
and were more frequently admitted to the ICU directly
from the emergency department. Patients without any
respiratory tract infection were less likely to have
hematological disease. SOFA score was higher in pa-
tients with influenza and co-infection, mainly driven by
higher SOFA respiratory subscores in this group. When
excluding patients negative for influenza but with no
testing done, only patients with influenza alone were
more likely to have solid tumors (Additional file 1: Table
S1). Intubation during the ICU stay was higher and
shock lower in patients with influenza and co-infection
compared to the other groups (Table 2).
Outcomes on crude, propensity score-matched, and
multivariate analysis
Outcomes in the different exposure groups in the crude
analysis are summarized in Table 2. ICU mortality dif-
fered between the four groups (P < 0.001), with the high-
est mortality in patients with influenza plus co-infection
(41%) and non-influenza infection (37%) and slightly
lower mortality in influenza infection alone (33%) and in
those without infection (26%). When the analyses
were performed, after excluding those patients nega-
tive for influenza but with no testing done, similar re-
sults were found (Additional file 2: Table S2).
Hospital and day 90 mortality showed a trend with
the highest mortality in patients with influenza plus
co-infection (52%) and non-influenza infection (46%)
respectively (Table 2 and Additional file 2: Table S2).
Survival curves for ICU and hospital stay for the four
Table 1 Influenza infection status and baseline characteristics at ICU admission
Baseline characteristics No infection (n
= 638)
Infection other than
influenza (n = 820)
Influenza alone
(n = 95)
Influenza co-infection
(n = 58)
P
valueb
Age (years), median [IQR] 63 [54–71] 63 [55–71] 65 [54–72] 64 [52–70] 0.80
Gender, male 351 (55) 512 (63) 59 (63) 32 (56) 0.04
Obesitya 108 (17) 151 (18) 21 (22) 12 (21) 0.21
Underlying disease
Hematological disease 311 (49) 436 (53) 60 (63) 30 (51) 0.05
Solid tumor 252 (39) 285 (35) 18 (19) 12 (21) <
0.001
Solid organ transplantation 51 (9) 75 (10) 7 (8) 9 (16) 0.4
Systemic disease or other ID 102 (16) 133 (16) 25 (26) 18 (31) 0.002
Disease status at ICU admission
Newly diagnosed 161 (36) 154 (27) 12 (17) 7 (20) 0.0004
Remission 67 (15) 82 (14) 15 (21) 8 (23)
No remission 62 (14) 68 (12) 3 (4) 6 (17)
Allogeneic stem cell transplant 56 (9) 82 (10) 9 (9) 5 (9) 0.03
ECOGc≥ 2 (severely disabled or bedridden) 210 (33) 299 (36) 36 (38) 23 (40) 0.15
Comorbidities
Cardiac 141 (24) 167 (22) 16 (18) 15 (27) 0.43
COPD 103 (17) 123 (15) 14 (15) 7 (12) 0.80
Kidney 88 (14) 117 (15) 16 (18) 10 (17) 0.75
Diabetes 108 (17) 161 (20) 21 (22) 14 (25) 0.30
Alcohol use disorder 63 (10) 76 (10) 5 (5) 4 (7) 0.48
Tobacco use 199 (33) 228 (29) 21 (23) 12 (21) 0.08
Duration of symptoms before ICU admission
(days), median [IQR]
1 [0–4] 1 [0–3] 2 [1–7] 1.5 [1–4] <
0.001
Admission from emergency department 208 (33) 256 (32) 41 (43) 19 (33) 0.17
Neutropenia at admission 66 (11) 153 (20) 20 (21) 12 (21) <
0.001
Data are presented as median [IQR] or N (%)
aObesity grade I, II and extreme obesity
bChi-squared test of association with three degrees of freedom
cEastern Cooperative Oncology Group (ECOG) performance status score
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groups are presented in Fig. 1. Hospital survival did
not differ by group (P = 0.11).
For the propensity score-matched analysis, 152 pa-
tients with influenza were matched. One patient with in-
fluenza could not be matched and was excluded from
the analysis. Imbalances in confounders were reduced
after matching (Fig. 2). In the matched sample, there
was no difference in hospital mortality attributable to in-
fluenza infection (OR = 1.01, 95%CI 0.90–1.13, P = 0.85).
Table 3 shows the results of multivariate analysis after
multiple imputation by chained equations. The following
factors were associated with hospital mortality: age, dir-
ect ICU admission, severity manifested by SOFA score,
diagnosis of ARDS, and performance status, with the lat-
ter two demonstrating the strongest association with OR
of hospital mortality of 1.53 and 1.44 respectively. None
of the mechanism and/or type of immunosuppression
was found as an independent risk factor for hospital
mortality. When the analysis was performed in patients
negative for influenza and the test not done, similar re-
sults were found (Table 3).
Discussion
In summary, our multinational observational study ana-
lyzed 1611 immunosuppressed patients from 68 centers
and found that if a critically ill immunosuppressed pa-
tient is infected with influenza, the outcome depends on
the immunosuppression (independently of the mechan-
ism and/or type of immunosuppression) rather than in-
fluenza infection. We found that independent risk
factors for hospital mortality were age, organ dysfunc-
tion severity, direct admission to the ICU, and especially
a diagnosis of ARDS and performance status. Influenza
plus co-infection with bacterial or fungal pathogens was
associated with the highest ICU mortality rate in our
study. We did not observe a statistically significant
Table 2 Association between influenza infection status, clinical characteristics at day 1, and outcomes
Variables No infection (n =
638)
Infection other than influenza (n
= 820)
Influenza alone (n
= 95)
Influenza & co-infection (n
= 58)
P
valuea
At day 1
Maximum respiratory rate
(breaths/min)
30 [24–36] 31 [25–37] 32 [28–36] 32 [26–38] 0.01
Liters/min O2 7 [3–15] 8 [5–15] 10 [4–15] 15 [2–15] 0.04
FiO2 50 [40–70] 50 [40–80] 50 [50–72] 59 [51–75] 0.03
PaO2/FiO2 ratio 173 [115–215] 110 [79–173] 113 [110–204] 127 [87–170] <
0.001
ARDS at day 1 481 (75) 737 (90) 92 (97) 57 (98) <
0.001
SOFA at ICU admission 6 [4–9] 7 [4–11] 7 [4–10] 8 [6–10] <
0.001
Respiratory SOFA = 0 103 (17) 94 (12) 9 (10) 1 (2) <
0.001
Cardiovascular SOFA = 0 334 (53) 341 (42) 34 (37) 25 (43) <
0.001
Outcome
Intubation during the ICU stay 357 (56) 57 (60) 530 (65) 47 (81) <
0.001
Shock 171 (27) 429 (52) 47 (49) 32 (36) <
0.001
Renal replacement therapy 93 (15) 140 (17) 17 (17) 17 (29) 0.04
Steroidsb 187 (33) 272 (36) 27 (31) 27 (49) 0.09
ICU-acquired pneumonia 47 (7) 96 (12) 14 (15) 6 (10) 0.01
ICU length of stay (days) 5 [2–10] 7 [3–15] 8 [4–21] 10.5 [5–20] <
0.001
ICU mortality 165 (26) 302 (37) 31 (33) 24 (41) <
0.001
Hospital mortality 251 (41) 365 (46) 36 (38) 30 (52) 0.09
Day 90 mortality 291 (45) 410 (50) 38 (40) 32 (55) 0.06
Data are presented as median, IQR, or N (%)
aChi-squared test of association with three degrees of freedom
bReceived steroids in ICU
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association between influenza infection status and hos-
pital mortality, our primary outcome, in either crude or
propensity score-matched analyses.
Influenza is a risk factor for acute respiratory failure in
immunosuppressed patients. However, its role as an in-
dependent risk factor for mortality in such a population
has been questioned [9]. The number of immunosup-
pressed patients hospitalized with influenza has in-
creased in recent years, and we showed that while
influenza alone may not increase mortality, influenza
plus co-infection may be associated with higher ICU
mortality. It might therefore be argued that empiric anti-
biotic treatment for co-infection in such patients should
be considered until the possibility of co-infection has
been confidently ruled out. To facilitate earlier detection
of co-infection, Rodriguez et al. [17] recently described
that a low level of procalcitonin (PCT) has a high nega-
tive predictive value (94%). However, clinicians may not
be willing to tolerate even a low probability of untreated
pulmonary co-infection in light of our observation that
this category was associated with higher ICU mortality
and length of stay.
In our cohort, two important factors stood out as in-
dependent risk factors for death: the need for intubation
during ICU stay and ARDS. While both features were
associated with increased mortality in any immunosup-
pressed patient, the mortality rate approached 100%
when this occurred in patients with influenza and
co-infection. Due to a known protective effect on mor-
tality of direct admission from the emergency depart-
ment to the ICU, it might be hypothesized that earlier
assessment for severity and therefore earlier ICU admis-
sion may improve the outcomes [18]. In a large popula-
tion of patients with influenza, Álvarez-Lerma et al. [19]
observed that ICU mortality was significantly higher
among patients with late diagnosis as compared with
early diagnosis (26.9% vs 17.1%, P < 0.001). Diagnostic
delay was one independent risk factor for mortality (OR
= 1.36, 95%CI 1.03–1.81, P < 0.001).
A common diagnostic challenge in immunosuppressed
patients is the lack of clinical symptoms when develop-
ing infections. In other words, an immunocompromised
host is a patient who does not have the ability to re-
spond normally to an infection due to an impaired or
Fig. 1 Hospital mortality and influenza infection status. Hospital mortality in the whole cohort according to influenza infection status categorized
by four groups: (1) patients with influenza alone, (2) patients with influenza plus co-infections (clinically or microbiologically confirmed bacterial or
fungal infection), (3) patients with infections other than influenza infection, and (4) patients without infection. Survival curves were compared
using Cox regression
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Fig. 2 Imbalances in confounders of mortality by influenza infection status before and after propensity score matching. Based on the matched
sample, there was no evidence of any difference in hospital mortality across groups (OR = 1.01, 95%CI 0.90–1.13, p = 0.85). We developed a
propensity score (PS) logistic model to have flu then matched the individuals on the basis of their PS using a 1:1 matching algorithm without
replacement within a caliper of 0.15 standard deviation of the logit of the propensity score. To handle missing values in confounders, multiple
imputation with chained equation was used for the PS model, where propensity score for each patient was averaged across 30 completed
datasets while propensity score matching used these averaged scores to estimate the treatment effect. Only 1 patient with influenza could not
be matched. Imbalances in confounders were reduced after matching
Table 3 Multivariate analysis of factors associated with hospital mortality after multiple imputations
Variable Assuming non-tested = negative Excluding non-tested
OR P value OR P value
No infection 1.00 1.00
Influenza alone 0.79 (0.49–1.27) 0.33 0.96 (0.51–1.78) 0.89
Infection other than influenza 1.02 (0.81–1.29) 0.85 1.28 (0.85–1.93) 0.23
Influenza co-infection 1.21 (0.68–2.15) 0.51 1.94 (0.84–3.72) 0.09
Age 1.01 (1.003–1.019) 0.0031 1.01 (1.003–1.019) 0.0051
Direct admission 0.72 (0.57–0.91) 0.0061 0.73 (0.53–0.99) 0.0042
SOFA score 1.14 (1.107–1.171) < 0.0001 1.15 (1.11–1.19) < 0.0001
ARDS 1.53 (1.12–2.10) 0.0084 1.57 (0.97–2.53) 0.065
ECOG 1.44 (1.29–1.61) < 0.0001 1.46 (1.27–1.67) < 0.0001
Mechanism and/or type of immunosuppression was not found as an independent risk factor/s for hospital mortality
Martin-Loeches et al. Critical Care          (2019) 23:152 Page 7 of 10
weakened immune system. This has been well reported
in cases of bacterial or fungal infections, but little is
known in the case of viral infections [20]. In our cohort,
we found that patients with influenza were actually more
likely to have a longer duration of symptoms prior to
ICU admission.
Hypoxemia is a common clinical feature of patients with
influenza, especially in immunosuppressed hosts. In a re-
cent report from two cancer centers describing the out-
comes in patients with hematological malignancies and
influenza infection, severe hypoxemia was an independent
risk factor (OR 5.87, 1.12–30.77) for 60-day mortality [21].
Similarly, hypoxemia was clearly a signal of illness severity
in our study. In patients not intubated at admission to the
ICU, oxygen requirements and ICU mortality rates were
greatest in those with influenza plus co-infection.
Co-infection has previously been reported as an inde-
pendent risk factor for poor outcome in patients with in-
fluenza [9]. In our cohort, patients with co-infection
were less likely to be cancer patients (have a
hematological disease or solid tumor) but were more
likely to have newly diagnosed immunosuppressive sys-
temic disease or have poorer functional capacity. In this
population, the criteria that suggest co-infection and
therefore higher severity may be higher oxygen require-
ments, greater tachypnea and work of breathing, and
higher rates of mechanical ventilation.
Systemic immune mechanisms play a key role in the
development of co-infection based on the complexity of
the interaction of the host and the viral and bacterial
pathogens. Several studies have been performed to de-
termine the point prevalence of bacterial co-infection in
influenza patients [9, 22–24]. In our cohort, almost half
of the patients with co-infection received steroids. The
use of steroids has been controversial and is currently
not recommended in patients with influenza [25]. This
is particularly relevant to our studied population because
many patients were already receiving corticosteroid ther-
apy for their primary disease. It appears plausible that
steroids were given as a stress response treatment in pa-
tients that were using longer-term steroids and not as a
treatment for influenza per se. Importantly, we did not
find steroids to be a risk factor for hospital mortality.
Some limitations should be mentioned. Vaccination
status and information on antiviral regimen, dose, dur-
ation, and delay in the start of therapy were not col-
lected. Similar limitations apply to the determination of
co-infection, which also could have led to misclassifica-
tion error and bias. The sample contained primarily pa-
tients with underlying hematological disease. Other
subgroups of immunocompromised patients (particularly
patients with lung transplant) may be underrepresented
which may limit generalizability. Additionally, we did
not completely account for the effect of the type of
immunosuppressive regimen in the adjusted analysis.
The propensity score analysis aims at controlling for
confounders, including those variables associated with
the immunodeficiency that may affect the outcome.
Nevertheless, one cannot assume that all confounders—
possibly even not observed—have been taken into ac-
count and that there may be residual confounders.
Conclusion
In summary age, severity score, ARDS, and performance
status were all independent risk factors for ICU, hospital,
and 90-day mortality in immunosuppressed patients ad-
mitted to the ICU for acute hypoxemic respiratory failure.
The main aim in this paper was to determine if influenza
alone or co-infection played a role in the mortality in ICU
patients. Category of infectious etiology of respiratory fail-
ure (influenza, non-influenza, influenza plus co-infection,
and non-infectious) was associated with ICU but not hos-
pital mortality. In a propensity score-matched analysis, in-
fluenza infection was not associated with the primary
outcome of hospital mortality. Overall, influenza infection
alone is not an independent risk factor for hospital mor-
tality in immunosuppressed patients.
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